Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden — Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials

Bjerke, 2010, Confounding factors influencing amyloid beta concentration in cerebrospinal fluid, Int. J. Alzheimers Dis., 2010, 986310 Bloom, 2009, Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype, Dement. Geriatr. Cogn. Disord., 27, 458, 10.1159/000216841 Bossuytt, 2003, Standard for Reporting Diagnostic Criteria (STARD criteria), BMJ, 326, 41 Bouwman, 2007, CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment, Neurobiol. Aging, 28, 1070, 10.1016/j.neurobiolaging.2006.05.006 Buchhave, 2008, Cube copying test in combination with rCBF or CSF A beta 42 predicts development of Alzheimer's disease, Dement. Geriatr. Cogn. Disord., 25, 544, 10.1159/000137379 Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria, Lancet Neurol., 6, 734, 10.1016/S1474-4422(07)70178-3 Fagan, 2007, Cerebrospinal fluid tau/beta-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults, Arch. Neurol., 64, 343, 10.1001/archneur.64.3.noc60123 Hampel, 2010, Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives, Nat. Drug Discov., 9, 560, 10.1038/nrd3115 Hansson, 2006, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol., 5, 228, 10.1016/S1474-4422(06)70355-6 Hansson, 2007, Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment, Dement. Geriatr. Cogn. Disord., 23, 316, 10.1159/000100926 Hansson, 2009, Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease, Neurobiol. Aging, 30, 165, 10.1016/j.neurobiolaging.2007.06.009 Mattsson et al, 2010, Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall, Clin. Chem. Lab. Med., 48, 603, 10.1515/CCLM.2010.131 Mattsson, 2009, CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, JAMA, 302, 385, 10.1001/jama.2009.1064 Shaw, 2009, Alzheimer's disease neuroimaging initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects, Ann. Neurol., 65, 403, 10.1002/ana.21610 Teunissen, 2010, Standardization of assay procedures for analysis of the CSF biomarkers amyloid β(1–42), tau, and phosphorylated tau in Alzheimer's disease: report of an international workshop, Int. J. Alzheimers Dis., 10.4061/2010/635053 van Rossum, 2010, Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design, J. Alzheimers Dis., 20, 881, 10.3233/JAD-2010-091606 Vemuri, 2009, MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change, Neurology, 73, 294, 10.1212/WNL.0b013e3181af79fb Visser, 2009, Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study, Lancet Neurol., 8, 619, 10.1016/S1474-4422(09)70139-5